Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Puma Biotechnology has entered into an agreement to develop and commercialize Pfizer's investigational cancer drug - Neratinib.
Subscribe to our email newsletter
Neratinib is a multi-targeted, irreversible tyrosine kinase inhibitor (TKI) oral drug which targets the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases.
Neratinib is being studied in the neoadjuvant, adjuvant and advanced settings in HER2/ErbB2 positive breast cancer.
Pfizer said it will award payments upon Puma’s achievement of certain development milestones for neratinib, as well as royalty payments for any sales of neratinib.